SCHEMBL6429546

SCHEMBL6429546

O=C1C(c2ccccn2)=C(C(F)(F)F)C(=O)N1Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.40
NR1H2 P55055 2/20 0.40
NR1H3 Q13133 2/20 0.40
HTR7 P34969 1/20 0.40
HTR6 P50406 1/20 0.40
CASP3 P42574 1/20 0.39
F2 P00734 1/20 0.39
PLG P00747 1/20 0.39
ELANE P08246 1/20 0.39
CTSG P08311 1/20 0.39
CMA1 P23946 1/20 0.39
CTRC Q99895 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.38
PKM P14618 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6428246 0.86 GSK3B (0.39) NR1H2NR1H3CASP3F2PLG
SCHEMBL6426236 0.81 MAPT (0.46) NR1H2NR1H3CASP3F2PLG
SCHEMBL6426783 0.80 NR1H2 (0.47) NR1H2NR1H3CASP3F2PLG
SCHEMBL6427487 0.77 DHPS (0.46) NR1H2NR1H3CYP2C19ALDH1A1
SCHEMBL6428548 0.76 NR1H2 (0.56) NR1H2NR1H3CASP3F2PLG
SCHEMBL6429398 0.75 NPSR1 (0.41) NR1H2NR1H3CASP3F2PLG
SCHEMBL6525603 0.72 NR1H2 (0.41) NR1H2NR1H3CASP3F2PLG
SCHEMBL6427166 0.71 CASP1 (0.47) NR1H2NR1H3CASP3CYP1A2CYP2C19
SCHEMBL6429024 0.71 PTGS2 (0.46) NR1H2NR1H3
SCHEMBL6427122 0.68 NR1H2 (0.47) NR1H2NR1H3MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005024755-A2 MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR DIABETES DECIPHERA PHARMACEUTICALS, LLC. (US) 2005-03-17 WO disclosed